Clinical human papillomavirus detection forecasts cervical cancer risk in women over 18 years of follow-up.

@article{Castle2012ClinicalHP,
  title={Clinical human papillomavirus detection forecasts cervical cancer risk in women over 18 years of follow-up.},
  author={Philip E. Castle and Andrew Glass and Brenda B. Rush and David R Scott and Nicolas Wentzensen and Julia C. Gage and Julie Helen Buckland and Greg Rydzak and Attila T Lorincz and Sholom Wacholder},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2012},
  volume={30 25},
  pages={
          3044-50
        }
}
PURPOSE To describe the long-term (≥ 10 years) benefits of clinical human papillomavirus (HPV) DNA testing for cervical precancer and cancer risk prediction. METHODS Cervicovaginal lavages collected from 19,512 women attending a health maintenance program were retrospectively tested for HPV using a clinical test. HPV positives were tested for HPV16 and HPV18 individually using a research test. A Papanicolaou (Pap) result classified as atypical squamous cells of undetermined significance (ASC… CONTINUE READING
Highly Cited
This paper has 30 citations. REVIEW CITATIONS
Tweets
This paper has been referenced on Twitter 17 times. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 21 citations